KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Non Operating Income (2024 - 2025)

Biocryst Pharmaceuticals' Non Operating Income history spans 2 years, with the latest figure at -$12.4 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 42.43% year-over-year to -$12.4 million; the TTM value through Dec 2025 reached -$73.6 million, up 12.81%, while the annual FY2025 figure was -$73.6 million, 12.81% up from the prior year.
  • Non Operating Income reached -$12.4 million in Q4 2025 per BCRX's latest filing, up from -$17.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of -$12.4 million in Q4 2025 to a low of -$23.3 million in Q2 2025.